Cerevel Therapeutics Holdings Management

Management Kriterienprüfungen 2/4

Cerevel Therapeutics Holdings' CEO ist Ron Renaud , ernannt in Jun 2023, hat eine Amtszeit von 1.08 Jahren. Die jährliche Gesamtvergütung beträgt $32.32M , bestehend aus 1.2% Gehalt und 98.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.13% der Aktien des Unternehmens, im Wert von $9.99M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.6 Jahre bzw. 5.3 Jahre.

Wichtige Informationen

Ron Renaud

Geschäftsführender

US$32.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	1.2%
Amtszeit als Geschäftsführer	1.1yrs
Eigentum des Geschäftsführers	0.1%
Durchschnittliche Amtszeit des Managements	3.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.3yrs

Jüngste Management Updates

Recent updates

Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Apr 30

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jan 02

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Jul 08

Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Jul 14

We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Jun 09

Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Jan 29

Cerevel Therapeutics (CERE) Investor Presentation - Slideshow

Nov 18

Cerevel Therapeutics reports Q3 results

Nov 16

Dosing underway in Cerevel Therapeutics' tavapadon trials for Parkinson’s disease

Oct 30

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Ron Renaud im Vergleich zu den Einnahmen von Cerevel Therapeutics Holdings verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$460m
Dec 31 2023	US$32m	US$375k	-US$433m

Vergütung im Vergleich zum Markt: RonDie Gesamtvergütung ($USD32.32M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD8.44M).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Ron mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Ron Renaud (55 yo)

1.1yrs

Amtszeit

US$32,322,358

Vergütung

Mr. Ronald C. Renaud, also known as Ron, Jr., M.B.A., serves as President, CEO & Director at Cerevel Therapeutics Holdings, Inc. since June 12, 2023. He served as Managing Director at Bain Capital Life Sci...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
N. Coles	Executive Chairman	5.7yrs	US$31.98m	0.0086% $ 670.6k
Ronald Renaud	President	1.1yrs	US$32.32m	0.13% $ 10.5m
Susan Altschuller	Chief Financial Officer	1.2yrs	US$4.63m	0.0093% $ 725.3k
Mark Bodenrader	Senior VP of Finance & Chief Accounting Officer	4.8yrs	US$1.21m	0.0097% $ 760.5k
John Renger	Chief Scientific Officer	5.3yrs	US$3.45m	0.0035% $ 273.6k
Ramiro Sanchez	Chief Medical Officer	5.5yrs	US$4.13m	0.0080% $ 629.2k
Paul Burgess	Chief Business Development & Strategic Operations Officer	1.1yrs	US$3.55m	0.025% $ 2.0m
Matthew Calistri	Vice President of Investor Relations	no data	keine Daten	keine Daten
Scott Akamine	Chief Legal Officer & Corporate Secretary	3.2yrs	US$3.19m	0.0040% $ 310.3k
Kenneth DiPietro	Chief Human Resources Officer	5.3yrs	keine Daten	0.014% $ 1.1m
Kathleen Tregoning	Chief Corporate Affairs Officer & Head of Commercial Strategy	4yrs	US$3.92m	0.0059% $ 457.2k

3.6yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: CEREDas Führungsteam des Unternehmens gilt als erfahren (3.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
N. Coles	Executive Chairman	5.7yrs	US$31.98m	0.0086% $ 670.6k
Ronald Renaud	President	1.1yrs	US$32.32m	0.13% $ 10.5m
Gabrielle Greene-Sulzberger	Independent Director	5.1yrs	US$513.93k	0.027% $ 2.1m
Marijn Dekkers	Independent Director	5.8yrs	US$486.49k	0.017% $ 1.4m
Deval Patrick	Independent Director	3.5yrs	US$485.48k	0.0018% $ 140.7k
Norbert Riedel	Lead Independent Director	5.6yrs	US$564.65k	0.025% $ 2.0m
Christopher Gordon	Independent Director	5.8yrs	US$501.43k	0.0018% $ 140.7k
Adam Koppel	Independent Director	5.8yrs	US$504.65k	0.0018% $ 140.7k
Douglas Giordano	Independent Director	5.8yrs	US$505.21k	0.0018% $ 140.7k
Ruth McKernan	Independent Director	3.6yrs	US$485.48k	0% $ 0
Suneet Varma	Independent Director	2.1yrs	keine Daten	keine Daten
Deborah Baron	Independent Director	3.5yrs	keine Daten	keine Daten

5.3yrs

Durchschnittliche Betriebszugehörigkeit

62.5yo

Durchschnittliches Alter

Erfahrener Vorstand: CEREDie Vorstandsmitglieder gelten als erfahren (5.3 Jahre durchschnittliche Amtszeit).

Cerevel Therapeutics Holdings Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Recent updates

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Price target increased by 9.7% to US$36.60

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) for $8.2 billion.

Independent Director notifies of intention to sell stock

Cerevel Therapeutics Holdings, Inc. to Report Q3, 2023 Results on Nov 01, 2023

New minor risk - Shareholder dilution

Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $449.999991 million.

Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $449.999991 million.

Executive Chairman notifies of intention to sell stock

President recently bought US$2.0m worth of stock

Price target decreased by 8.1% to US$34.13

Price target decreased by 7.4% to US$34.38

Executive Chairman notifies of intention to sell stock

Cerevel Therapeutics Holdings, Inc. to Report Q2, 2023 Results on Aug 02, 2023

High number of new directors

Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer, Effective from June 20, 2023

Executive Chairman & CEO notifies of intention to sell stock

Cerevel Therapeutics Appoints Susan Altschuller as Chief Financial Officer

Executive Chairman & CEO notifies of intention to sell stock

Cerevel Therapeutics Holdings, Inc. Announces Executive Changes

Price target decreased by 8.8% to US$35.20

Executive Chairman & CEO notifies of intention to sell stock

Price target decreased by 9.3% to US$37.09

Executive Chairman & CEO notifies of intention to sell stock

Executive Chairman & CEO exercised options and sold US$1.5m worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Executive Chairman & CEO exercised options and sold US$1.3m worth of stock

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Executive Chairman & CEO exercised options and sold US$1.2m worth of stock

Chief Scientific Officer exercised options and sold US$561k worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chief Scientific Officer exercised options and sold US$561k worth of stock

Cerevel overweight at Wells Fargo due to candidates with blockbuster potential

Price target increased to US$43.29

President exercised options and sold US$371k worth of stock

President exercised options and sold US$186k worth of stock

Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $253.75 million.

Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering

President notifies of intention to sell stock

Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13

Cerevel Therapeutics Holdings, Inc. to Report Q2, 2022 Results on Aug 01, 2022

Chief Scientific Officer exercised options and sold US$663k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Price target decreased to US$39.71

Cerevel Therapeutics Appoints Suneet Varma to Serve as Member of Its Board of Directors

Chief Scientific Officer exercised options and sold US$1.4m worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q1, 2022 Results on May 10, 2022

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$1.2m worth of stock

Chief Scientific Officer exercised options and sold US$895k worth of stock

Chief Scientific Officer exercised options and sold US$663k worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety

Chief Scientific Officer exercised options and sold US$663k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Price target increased to US$46.33

Price target decreased to US$32.67

Price target increased to US$36.33

Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Cerevel Therapeutics Holdings, Inc. Announces Positive Topline Results for Cvl-231 in Phase 1B Clinical Trial in Patients with Schizophrenia